Hormone Replacement Therapy: Product Shortage
Thursday, 22 October 2026
Contributions
Question
Asked by
Baroness Nargund
To ask His Majesty’s Government what assessment they have made of the potential impact on menopausal women of the hormone replacement therapy product shortage.
The Parliamentary Under-Secretary of State, Department of Health and Social Care (Baroness Merron) (Lab)
My Lords, most of the 70 HRT products available in the UK remain in good supply; three are currently affected and alternative products are available. To mitigate any impact on patients, we have expedited deliveries, issued comprehensive NHS guidance and introduced serious shortage protocols to allow pharmacists to supply alternative brands without the need to return to prescribers. We continue to work with suppliers, regulators and importers.
Baroness Nargund (Lab)
My Lords, I thank my noble friend the Minister for her reply. Nearly 2 million women aged 40 or above are currently prescribed HRT as an essential treatment, so I thank the Government for taking those steps. What steps are they taking to strengthen the resilience of the HRT supply chain to prevent future shortages? I know that the news of shortages causes significant anxiety to women who are on HRT and the shortages cause enormous disruption to their care, particularly when it is an essential treatment.
Baroness Merron (Lab)
I recognise that uncertainty can affect somebody’s emotional and physical well-being. That is why it is important to use the opportunity—I am grateful to my noble friend—to give reassurance about the contained scale of this. On the point about supply resilience, which is indeed what we are working on, we set out our actions last year to improve shortage management and strengthen supply chains. We have also taken forward work to strengthen UK medicines manufacturing, to improve our understanding of supply chains and, importantly, to identify potential risks earlier. I can assure my noble friend that we will be publishing an update later this year.
Baroness Pidgeon (LD)
My Lords, HRT, like all medicines, is not a nice-to-have but critical to many women. The Public Services Committee, in its report on medicines security published in February, concluded that medicines security should be treated as a national priority and feature on the risk register. Do the Government now agree?
Baroness Merron (Lab)
It is a priority for sure. On the point the noble Baroness raised on HRT, there were significant supply pressures in 2022, but that has been contained. I am glad that we are approaching this as we approach other shortages elsewhere; for example, through protocols. As I have explained, there are alternatives. I understand the concerns it might generate, but it is important that we advise women—for whom, I agree, this is crucial—that a range of products and formulations are available, and pharmacists and GPs are well able to assist and ensure that they do not go without their medication.
Baroness Verma (Con)
My Lords, will the Minister look at the serious issue of vaginal dryness during menopause and the fact that many women cannot always access or afford over-the-counter products, seeing this as a crucial part of not just the well-being of the person going through the menopause but the wider context of relationships? Will she see how we can make products much more affordable if not prescribed?
Baroness Merron (Lab)
I certainly agree about the importance of that and various aspects of menopause and the need to support and, where necessary, prescribe. There is, indeed, oestrogen replacement which is prescribable. On cost, we have introduced the HRT prescription prepayment certificate—which many women have taken advantage of, I am glad to say—which ensures that eligible HRT prescriptions are available for £19.80 for a whole year. Some 89% of prescriptions generally are in any case free, and we have pegged the costs for a further year to ensure that anyone paying is still paying under £10.
Baroness Gohir (CB)
My Lords, I understand that research shows that there is a lower uptake of HRT among Black and Asian women. Do the Government know why that is and what they are doing about it?
Baroness Merron (Lab)
We have invested in new research just this year to build on workplace support for nurses and midwives who are working in health and social care during menopause. We are also looking at improving quality of life, particularly where there are disparities in ethnicity in respect of HRT use and particularly in older women, who may also be unaware of and excluded from the support available. These ongoing studies will assist us to make it more widely available.
Baroness Bousted (Lab)
Does the Minister agree that secure provision of HRT is not a new issue and has been going on for years? It causes women huge fear and anxiety. Does she share my suspicion that if men needed HRT, there would be less disruption to supply?
Baroness Merron (Lab)
I could not possibly comment. However, it is important to acknowledge that concern among women or any other group. It can be very distressing and worrying, and it is why we have taken all the actions that I have already described. I emphasise that the significant supply pressures on HRT go back to 2022 and there have been considerable improvements. To reiterate, we are talking about three products out of 70 and there are alternatives available. I encourage any woman who is concerned to speak to her GP or pharmacist to get the reassurance and the care she needs.
Baroness Hussein-Ece (LD)
My Lords, despite the investment in HRT and the amount of research and guidance, there are still variations across the regions and the country in take-up and the advice that women are given by their GPs, who are sometimes reluctant to prescribe it. Just last week, I heard of the case of a woman I know who was suffering from anxiety and severe symptoms of menopause, but she was advised by her GP that she had mental health problems and needed to see a mental health specialist and maybe take anti-depressants—she did not. I am concerned about such variation and inconsistency across the country. I would welcome the Minister assuring me that this is being looked at.
Baroness Merron (Lab)
The noble Baroness raises an important point, and I can give her that assurance. The focus on menopause is a key part of the women’s health strategy which we published earlier this year. On her point about clinicians, I am sure she will be pleased to know that, just last month, we introduced a new and updated medical licensing assessment. Anyone graduating from medical school is required to pass that, which means that they will have a better understanding. We are also developing a range of tools and interventions to support existing GPs to upskill. I am sure that the noble Baroness will welcome the fact that we are, for the first time ever, introducing menopause into NHS health checks.
Baroness Griffin of Princethorpe (Lab)
My Lords, women in less deprived areas are twice as likely to be prescribed HRT as women in more deprived areas. Can my noble friend the Minister say what steps will be taken to address equity of access?
Baroness Merron (Lab)
Inequity of access is not acceptable, but I know that it exists in all sorts of ways. We are improving the evidence base so that we can address those inequalities. As I said earlier, I am looking forward to the research on socioeconomic and ethnic disparities—but also important is, for example, the action we have taken to make HRT more affordable and to improve its availability to those who do not have to pay.
Source: UK Parliament Hansard API. Debate ID: 5423188.